EPS for Acerus Pharmaceuticals Corporation (ASP) Expected At $-0.04

August 9, 2018 - By Jason Dias

Acerus Pharmaceuticals Corporation (TSE:ASP) Logo

Analysts expect Acerus Pharmaceuticals Corporation (TSE:ASP) to report $-0.04 EPS on August, 10.They anticipate $0.03 EPS change or 300.00 % from last quarter’s $-0.01 EPS. After having $-0.03 EPS previously, Acerus Pharmaceuticals Corporation’s analysts see 33.33 % EPS growth. It closed at $0.225 lastly. It is down 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Acerus Pharmaceuticals Corporation focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for men's urology and women's hormone replacement therapy, and female sexual dysfunction. The company has market cap of $52.93 million. The company's approved products include Natesto, a bioadhesive nasal gel formulation of testosterone; and Estrace, an oral tablet for the symptomatic relief of menopausal symptoms. It currently has negative earnings. It is also developing Gynoflo for the treatment of symptoms of vaginal atrophy; and Tefina, a nasal and low-dose gel formulation of testosterone that has been completed Phase II trials for the symptoms of female sexual dysfunction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.